Integrated BioPharma, Inc.
INBP · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $54,353 | $50,317 | $50,672 | $56,246 |
| % Growth | 8% | -0.7% | -9.9% | – |
| Cost of Goods Sold | $48,791 | $46,433 | $46,611 | $49,694 |
| Gross Profit | $5,562 | $3,884 | $4,061 | $6,552 |
| % Margin | 10.2% | 7.7% | 8% | 11.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3,542 | $3,633 | $3,941 | $3,807 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3,542 | $3,633 | $3,941 | $3,807 |
| Operating Income | $2,020 | $251 | $120 | $1,966 |
| % Margin | 3.7% | 0.5% | 0.2% | 3.5% |
| Other Income/Exp. Net | $42 | $17 | -$20 | -$148 |
| Pre-Tax Income | $2,062 | $268 | $100 | $2,597 |
| Tax Expense | $1,254 | $156 | $134 | -$1,241 |
| Net Income | $808 | $112 | -$34 | $3,838 |
| % Margin | 1.5% | 0.2% | -0.1% | 6.8% |
| EPS | 0.027 | 0.004 | -0.001 | 0.13 |
| % Growth | 621.6% | 436.4% | -100.8% | – |
| EPS Diluted | 0.026 | 0.004 | -0.001 | 0.12 |
| Weighted Avg Shares Out | 30,296 | 30,066 | 29,950 | 29,843 |
| Weighted Avg Shares Out Dil | 31,168 | 30,874 | 29,950 | 32,321 |
| Supplemental Information | – | – | – | – |
| Interest Income | $85 | $70 | $13 | $0 |
| Interest Expense | $46 | $52 | $40 | $128 |
| Depreciation & Amortization | $1,269 | $1,221 | $1,154 | $834 |
| EBITDA | $3,377 | $1,472 | $1,274 | $3,559 |
| % Margin | 6.2% | 2.9% | 2.5% | 6.3% |